NCOA2
Overview
NCOA2 (Nuclear Receptor Coactivator 2) encodes a transcriptional coactivator that interacts with nuclear hormone receptors, including the androgen receptor (AR). In prostate cancer, NCOA2 amplification at 8q13.3 enhances AR signaling, driving tumor growth, and has been identified as a candidate oncogene.
Alterations observed in the corpus
- Amplification at 8q13.3 and somatic mutations detected in ~11% of prostate cancer tumors; enhances AR signaling and classified as an oncogene in integrative genomic profiling of 218 tumors PMID:20579941
Cancer types (linked)
- Prostate adenocarcinoma (PRAD): amplification in ~11% of tumors; functions as an AR pathway oncogene PMID:20579941
Co-occurrence and mutual exclusivity
- Co-occurs with TMPRSS2-ERG fusion in the context of AR pathway activation in prostate cancer PMID:20579941
Therapeutic relevance
- As an AR coactivator, NCOA2 amplification may contribute to castration resistance; relevant to androgen deprivation therapy response PMID:20579941
Open questions
- Functional validation of NCOA2 as a driver oncogene versus a passenger amplification remains incomplete.
Sources
This page was processed by entity-page-writer on 2026-05-06.